Assertio Therapeutics completed the merger with Zyla.

Assertio Therapeutics, an American specialty pharmaceutical company, completed the merger with Zyla Life Sciences, a specialty pharmaceutical company. Zyla stockholders received 2.5 shares of common stock of a newly-formed holding company for each share of Zyla common stock held. “Today’s announcement represents an exciting new chapter in the transformation of Assertio and the Merger presents the perfect opportunity for me to transition into the role of non-executive chairman. With over 25 years of pharmaceutical, medical device and biotechnology experience and a proven track record of success, Todd Smith has the leadership and business skills necessary to take the new Assertio to the next level,” Arthur Higgins, Assertio President and CEO.